Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study | Zendy

Sean Wasserman | Zendy; James C. M. Brust | Zendy; Mahmoud Tareq Abdelwahab | Zendy; Francesca Little | Zendy; Paolo Denti | Zendy; Lubbe Wiesner | Zendy; Neel R. Gandhi | Zendy; Graeme Meintjes | Zendy; Gary Maartens | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study

Author(s) -

Sean Wasserman,

James C. M. Brust,

Mahmoud Tareq Abdelwahab,

Francesca Little,

Paolo Denti,

Lubbe Wiesner,

Neel R. Gandhi,

Graeme Meintjes,

Gary Maartens

Publication year - 2022

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkac019

Subject(s) - linezolid , medicine , toxicity , adverse effect , population , discontinuation , rifampicin , antibacterial agent , pharmacology , tuberculosis , antibiotics , pathology , biology , microbiology and biotechnology , vancomycin , staphylococcus aureus , environmental health , bacteria , genetics

Linezolid is recommended for treating drug-resistant TB. Adverse events are a concern to prescribers but have not been systematically studied at the standard dose, and the relationship between linezolid exposure and clinical toxicity is not completely elucidated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research